# PTC Inc.: financial statements, quarterly

PTC · Nasdaq · CIK 857005 · [Technology](/sectors/technology.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/ptc.md) · [Financials](/companies/ptc/financials.md) · [Filings](/companies/ptc/filings.md) · [Insiders](/companies/ptc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ptc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [547 d](/filings/0001193125-25-291326.md) | [550](/filings/0000950170-25-015530.md) | [603](/filings/0000950170-25-061801.md) | [519](/filings/0000950170-25-100879.md) | [627 d](/filings/0001193125-25-291326.md) | [565](/filings/0001193125-26-039347.md) | [636](/filings/0001193125-26-209869.md) | [644](/filings/0001193125-26-328444.md) | [894 d](/filings/0001193125-25-291326.md) | [686](/filings/0001193125-26-039347.md) | [774](/filings/0001193125-26-209869.md) | [600](/filings/0001193125-26-328444.md) |
| Cost of revenue | $m | [116 d](/filings/0001193125-25-291326.md) | [110](/filings/0000950170-25-015530.md) | [110](/filings/0000950170-25-061801.md) | [112](/filings/0000950170-25-100879.md) | [113 d](/filings/0001193125-25-291326.md) | [112](/filings/0001193125-26-039347.md) | [106](/filings/0001193125-26-209869.md) | [110](/filings/0001193125-26-328444.md) | [117 d](/filings/0001193125-25-291326.md) | [118](/filings/0001193125-26-039347.md) | [114](/filings/0001193125-26-209869.md) | [110](/filings/0001193125-26-328444.md) |
| Gross profit | $m | [431 d](/filings/0001193125-25-291326.md) | [440](/filings/0000950170-25-015530.md) | [493](/filings/0000950170-25-061801.md) | [407](/filings/0000950170-25-100879.md) | [514 d](/filings/0001193125-25-291326.md) | [453](/filings/0001193125-26-039347.md) | [530](/filings/0001193125-26-209869.md) | [534](/filings/0001193125-26-328444.md) | [777 d](/filings/0001193125-25-291326.md) | [568](/filings/0001193125-26-039347.md) | [661](/filings/0001193125-26-209869.md) | [490](/filings/0001193125-26-328444.md) |
| Research and development | $m | [102 d](/filings/0001193125-25-291326.md) | [106](/filings/0000950170-25-015530.md) | [107](/filings/0000950170-25-061801.md) | [110](/filings/0000950170-25-100879.md) | [110 d](/filings/0001193125-25-291326.md) | [116](/filings/0001193125-26-039347.md) | [111](/filings/0001193125-26-209869.md) | [117](/filings/0001193125-26-328444.md) | [115 d](/filings/0001193125-25-291326.md) | [120](/filings/0001193125-26-039347.md) | [124](/filings/0001193125-26-209869.md) | [116](/filings/0001193125-26-328444.md) |
| Operating income | $m | [121 d](/filings/0001193125-25-291326.md) | [119](/filings/0000950170-25-015530.md) | [180](/filings/0000950170-25-061801.md) | [95.8](/filings/0000950170-25-100879.md) | [194 d](/filings/0001193125-25-291326.md) | [116](/filings/0001193125-26-039347.md) | [223](/filings/0001193125-26-209869.md) | [210](/filings/0001193125-26-328444.md) | [434 d](/filings/0001193125-25-291326.md) | [221](/filings/0001193125-26-039347.md) | [296](/filings/0001193125-26-209869.md) | [167](/filings/0001193125-26-328444.md) |
| Interest expense | $m | [35.7 d](/filings/0001193125-25-291326.md) | [35.3](/filings/0000950170-25-015530.md) | [31.6](/filings/0000950170-25-061801.md) | [27.8](/filings/0000950170-25-100879.md) | [24.9 d](/filings/0001193125-25-291326.md) | [22.0](/filings/0001193125-26-039347.md) | [19.6](/filings/0001193125-26-209869.md) | [18.4](/filings/0001193125-26-328444.md) | [17.0 d](/filings/0001193125-25-291326.md) | [17.3](/filings/0001193125-26-039347.md) | [15.3](/filings/0001193125-26-209869.md) | [15.8](/filings/0001193125-26-328444.md) |
| Income tax | $m | [42.9 d](/filings/0001193125-25-291326.md) | [19.2](/filings/0000950170-25-015530.md) | [31.3](/filings/0000950170-25-061801.md) | [(1.6)](/filings/0000950170-25-100879.md) | [43.7 d](/filings/0001193125-25-291326.md) | [10.9](/filings/0001193125-26-039347.md) | [42.6](/filings/0001193125-26-209869.md) | [52.3](/filings/0001193125-26-328444.md) | [80.3 d](/filings/0001193125-25-291326.md) | [36.5](/filings/0001193125-26-039347.md) | [156](/filings/0001193125-26-209869.md) | [33.7](/filings/0001193125-26-328444.md) |
| Net income | $m | [45.6 d](/filings/0001193125-25-291326.md) | [66.4](/filings/0000950170-25-015530.md) | [114](/filings/0000950170-25-061801.md) | [69.0](/filings/0000950170-25-100879.md) | [127 d](/filings/0001193125-25-291326.md) | [82.2](/filings/0001193125-26-039347.md) | [163](/filings/0001193125-26-209869.md) | [141](/filings/0001193125-26-328444.md) | [348 d](/filings/0001193125-25-291326.md) | [167](/filings/0001193125-26-039347.md) | [591](/filings/0001193125-26-209869.md) | [119](/filings/0001193125-26-328444.md) |
| Diluted EPS | $ per share | not reported | [0.55](/filings/0000950170-25-015530.md) | [0.95](/filings/0000950170-25-061801.md) | [0.57](/filings/0000950170-25-100879.md) | not reported | [0.68](/filings/0001193125-26-039347.md) | [1.35](/filings/0001193125-26-209869.md) | [1.17](/filings/0001193125-26-328444.md) | not reported | [1.39](/filings/0001193125-26-039347.md) | [4.98](/filings/0001193125-26-209869.md) | [1.03](/filings/0001193125-26-328444.md) |
| Basic EPS | $ per share | not reported | [0.56](/filings/0000950170-25-015530.md) | [0.96](/filings/0000950170-25-061801.md) | [0.58](/filings/0000950170-25-100879.md) | not reported | [0.68](/filings/0001193125-26-039347.md) | [1.35](/filings/0001193125-26-209869.md) | [1.18](/filings/0001193125-26-328444.md) | not reported | [1.40](/filings/0001193125-26-039347.md) | [5.00](/filings/0001193125-26-209869.md) | [1.04](/filings/0001193125-26-328444.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [288](/filings/0000950170-24-127231.md) | [265](/filings/0000950170-24-010527.md) | [249](/filings/0000950170-24-052860.md) | [248](/filings/0000950170-24-089978.md) | [266](/filings/0001193125-25-291326.md) | [196](/filings/0000950170-25-015530.md) | [235](/filings/0000950170-25-061801.md) | [199](/filings/0000950170-25-100879.md) | [184](/filings/0001193125-26-328444.md) | [210](/filings/0001193125-26-039347.md) | [439](/filings/0001193125-26-209869.md) | [351](/filings/0001193125-26-328444.md) |
| Current assets | $m | [1,277](/filings/0000950170-24-127231.md) | [1,134](/filings/0000950170-24-010527.md) | [1,153](/filings/0000950170-24-052860.md) | [1,092](/filings/0000950170-24-089978.md) | [1,299](/filings/0001193125-25-291326.md) | [1,085](/filings/0000950170-25-015530.md) | [1,133](/filings/0000950170-25-061801.md) | [1,090](/filings/0000950170-25-100879.md) | [1,383](/filings/0001193125-26-328444.md) | [1,387](/filings/0001193125-26-039347.md) | [1,504](/filings/0001193125-26-209869.md) | [1,372](/filings/0001193125-26-328444.md) |
| Total assets | $m | [6,289](/filings/0000950170-24-127231.md) | [6,271](/filings/0000950170-24-010527.md) | [6,205](/filings/0000950170-24-052860.md) | [6,128](/filings/0000950170-24-089978.md) | [6,384](/filings/0001193125-25-291326.md) | [6,075](/filings/0000950170-25-015530.md) | [6,162](/filings/0000950170-25-061801.md) | [6,229](/filings/0000950170-25-100879.md) | [6,617](/filings/0001193125-26-328444.md) | [6,427](/filings/0001193125-26-039347.md) | [6,537](/filings/0001193125-26-209869.md) | [6,514](/filings/0001193125-26-328444.md) |
| Current liabilities | $m | [1,671](/filings/0000950170-24-127231.md) | [950](/filings/0000950170-24-010527.md) | [1,515](/filings/0000950170-24-052860.md) | [1,569](/filings/0000950170-24-089978.md) | [1,667](/filings/0001193125-25-291326.md) | [1,561](/filings/0000950170-25-015530.md) | [1,146](/filings/0000950170-25-061801.md) | [1,227](/filings/0000950170-25-100879.md) | [1,237](/filings/0001193125-26-328444.md) | [1,138](/filings/0001193125-26-039347.md) | [1,219](/filings/0001193125-26-209869.md) | [1,338](/filings/0001193125-26-328444.md) |
| Total liabilities | $m | [3,612](/filings/0000950170-24-127231.md) | [3,465](/filings/0000950170-24-010527.md) | [3,262](/filings/0000950170-24-052860.md) | [3,113](/filings/0000950170-24-089978.md) | [3,169](/filings/0001193125-25-291326.md) | [2,846](/filings/0000950170-25-015530.md) | [2,776](/filings/0000950170-25-061801.md) | [2,716](/filings/0000950170-25-100879.md) | [2,791](/filings/0001193125-26-328444.md) | [2,585](/filings/0001193125-26-039347.md) | [2,677](/filings/0001193125-26-209869.md) | [3,044](/filings/0001193125-26-328444.md) |
| Long-term debt | $m | [1,686](/filings/0000950170-24-127231.md) | [2,248](/filings/0000950170-24-010527.md) | [1,491](/filings/0000950170-24-052860.md) | [1,293](/filings/0000950170-24-089978.md) | [1,227](/filings/0001193125-25-291326.md) | [1,019](/filings/0000950170-25-015530.md) | [1,364](/filings/0000950170-25-061801.md) | [1,208](/filings/0000950170-25-100879.md) | [1,172](/filings/0001193125-26-328444.md) | [1,173](/filings/0001193125-26-039347.md) | [1,173](/filings/0001193125-26-209869.md) | [1,398](/filings/0001193125-26-328444.md) |
| Current portion of debt | $m | [9.4](/filings/0000950170-24-127231.md) | [12.5](/filings/0000950170-24-010527.md) | [515](/filings/0000950170-24-052860.md) | [518](/filings/0000950170-24-089978.md) | [521](/filings/0001193125-25-291326.md) | [525](/filings/0000950170-25-015530.md) | [25.0](/filings/0000950170-25-061801.md) | [25.0](/filings/0000950170-25-100879.md) | [25.0](/filings/0001193125-26-328444.md) | [25.0](/filings/0001193125-26-039347.md) | [25.0](/filings/0001193125-26-209869.md) | [25.1](/filings/0001193125-26-328444.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [2,677](/filings/0001193125-25-291326.md) | [2,807](/filings/0000950170-25-061801.md) | [2,943](/filings/0000950170-25-100879.md) | [3,015](/filings/0000950170-25-100879.md) | [3,214](/filings/0001193125-26-328444.md) | [3,230](/filings/0001193125-26-209869.md) | [3,386](/filings/0001193125-26-328444.md) | [3,513](/filings/0001193125-26-328444.md) | [3,826](/filings/0001193125-26-328444.md) | [3,842](/filings/0001193125-26-209869.md) | [3,860](/filings/0001193125-26-328444.md) | [3,470](/filings/0001193125-26-328444.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [49.8 d](/filings/0001193125-25-291326.md) | [187](/filings/0000950170-25-015530.md) | [251 d](/filings/0000950170-25-061801.md) | [214 d](/filings/0000950170-25-100879.md) | [98.1 d](/filings/0001193125-25-291326.md) | [238](/filings/0001193125-26-039347.md) | [281 d](/filings/0001193125-26-209869.md) | [244 d](/filings/0001193125-26-328444.md) | [104 d](/filings/0001193125-25-291326.md) | [270](/filings/0001193125-26-039347.md) | [321 d](/filings/0001193125-26-209869.md) | [261 d](/filings/0001193125-26-328444.md) |
| Capital expenditure | $m | [5.8 d](/filings/0001193125-25-291326.md) | [4.6](/filings/0000950170-25-015530.md) | [3.6 d](/filings/0000950170-25-061801.md) | [1.6 d](/filings/0000950170-25-100879.md) | [4.5 d](/filings/0001193125-25-291326.md) | [2.8](/filings/0001193125-26-039347.md) | [2.8 d](/filings/0001193125-26-209869.md) | [1.9 d](/filings/0001193125-26-328444.md) | [3.5 d](/filings/0001193125-25-291326.md) | [2.3](/filings/0001193125-26-039347.md) | [2.7 d](/filings/0001193125-26-209869.md) | [11.3 d](/filings/0001193125-26-328444.md) |
| Share repurchases | $m | [0.0 d](/filings/0001193125-25-291326.md) | [0.0](/filings/0000950170-25-015530.md) | [0.0 d](/filings/0000950170-25-061801.md) | [0.0 d](/filings/0000950170-25-100879.md) | [0.0 d](/filings/0001193125-25-291326.md) | [75.0](/filings/0001193125-26-039347.md) | [75.0 d](/filings/0001193125-26-209869.md) | [75.0 d](/filings/0001193125-26-328444.md) | [75.0 d](/filings/0001193125-25-291326.md) | [200](/filings/0001193125-26-039347.md) | [626 d](/filings/0001193125-26-209869.md) | [500 d](/filings/0001193125-26-328444.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [119](/filings/0000950170-24-010527.md) | [119](/filings/0000950170-24-052860.md) | [119](/filings/0000950170-24-089978.md) | [120](/filings/0000950170-25-015530.md) | [121](/filings/0000950170-25-061801.md) | [121](/filings/0000950170-25-100879.md) | [121](/filings/0001193125-26-039347.md) | [121](/filings/0001193125-26-209869.md) | [120](/filings/0001193125-26-328444.md) | [120](/filings/0001193125-26-039347.md) | [119](/filings/0001193125-26-209869.md) | [115](/filings/0001193125-26-328444.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 108,506,261 at 2026-07-29, from the cover of the [10-Q filed 2026-07-31](/filings/0001193125-26-328444.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.